TCTR20180903001尚未招募4 期
Bioequivalence study of an open-label, randomized, two-way crossover design with two-period, two-treatment, two-sequence of test product donepezil hydrochloride 10 mg orodispersible tablets and reference product (Aricept® Evess) in healthy Thai volu
Pharmacy Service Center, Faculty of Pharmacy, Chiang Mai University0 个研究点目标入组 28 人开始时间: 2018年9月3日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 45 Years（—）
- 性别
- All
入选标准
- •1)Male and female subjects aged between 18-45 years
- •2)Body Mass Index (BMI) between 18.5-25.0 kg/m2 and body weight not less than 45 kg
- •3)Healthy subjects based on medical history and physical examination
- •4)Normal or not clinically significant abnormal of clinical laboratory results including blood urea nitrogen (BUN), serum creatinine (SCr), AST, ALT, total bilirubin, direct bilirubin, alkaline phosphatase, total protein, fasting blood glucose, complete blood count, and urinalysis
- •5)Clinical laboratory result of hepatitis B is negative.
- •6)No clinically significant findings in vital sign measurement
- •7)Nonsmoker or stop smoking for at least 6 months
- •8)Females who participate in this study are:
- •8.1) Nonpregnant female (negative result for pregnancy test)
- •8.2) With childbearing potential, whom must commit to using acceptable non-hormonal contraceptive method of birth control for at least 2 weeks before and during the study and 2 weeks after drug administration in period 2 as judged by the clinical investigators, such as condoms, non-hormonal intrauterine device (IUD), or willing to remain abstinence (not engage in sexual intercourse)
- •8.3) Not currently breastfeeding
- •9) Subjects are able, willing, and likely to comply with study procedures and restrictions.
排除标准
- •1)Subjects with a history of allergy to donepezil or related structure of donepezil or other components in the formulation
- •2)Subjects with currently or history of alcohol addiction or drug abuse
- •3)Subjects with currently or history of severe asthma, lung disease, seizures, gastrointestinal bleeding or ulcer, heart rhythm problem, hepatic, renal, endocrine, or cardiovascular diseases or any other conditions that may affect , bioavailability of the medication or safety of the subjects
- •4) Subjects who use of any aged including vitamins, herbal products, and dietary supplement, within 14 days before and during the study
- •5)Subjects who are unable to refrain from consumption of orange, pamelo, grapefruit within 7 days before and during the study
- •6)breastfeeding who are unable to refrain from caffeine-containing beverages and foods such as tea, coffee, cocoa, cola, chocolate or energy drink for 3 days before and during the study
- •7)Subjects with positive urine drug abuse test (methamphetamine, cannabinoid and opiates)
- •8)Subjects with positive alcohol breath test
- •9)Subjects with a history of blood donation greater than 300 ml or significant blood loss within 90 days before the initiation of the study
- •10)Subjects who participate in other clinical trials within 90 days before the initiation of the study
研究者
相似试验
尚未招募
4 期
Bioequivalence study of an open-label, randomized, two-way crossover design with two-period, two-treatment, two-sequence of test product montelukast 10 mg film coated tablets and reference product (Singulair®) in healthy Thai volunteers under fasting conditioHealthy volunteersTCTR20191009002Pharmacy Service Center, Faculty of Pharmacy, Chiang Mai University28
尚未招募
4 期
Bioequivalence study of an open-label, randomized, two-way crossover design with two-period, two-treatment, two-sequence of test product lynestrenol 0.5 mg tablets and reference product (Exluton®) in healthy Thai female volunteers under fasting conditioHealthy volunteersTCTR20200421004Pharmacy Service Center, Faculty of Pharmacy, Chiang Mai University28
招募中
4 期
Bioequivalence Study of An Open-Label, Randomized, Two-Way Crossover Design with Two-Period, Two-Treatment, Two-Sequence of Test Product Metformin 850 mg Film-Coated Tablets and Reference Product (Glucophage®) in Healthy Thai Volunteers Under Fed ConditioHealthy volunteersTCTR20180619001Pharmacy Service Center, Faculty of Pharmacy, Chiang Mai University28
已完成
3 期
A clinical trial intended to compare safety and efficacy of two formulations in patients with metastatic Colorectal Cancer (mCRC).CTRI/2014/08/004868MABXIENCE SA100
未知
不适用
OPEN LABEL RANDOMIZED BIOEQUIVALENCE STUDY TO EVALUATE THEPHARMACOKINETIC (PK) AND SAFETY PROFILE OF BEVACIZUMABBIOSIMILAR (BEVZ92) IN COMBINATION WITH FOLFOX ORFOLFIRI VERSUS BEVACIZUMAB (AVASTIN®) IN COMBINATIONWITH FOLFOX OR FOLFIRI AS FIRST-LINE TREATMENT IN PATIENTSWITH METASTATIC COLORECTAL CANCER (MCRC)PER-076-13mAbxience S.A.,